Why Rocket Lab (RKLB) Stock Blasted Higher Today and Why Stifel Thinks It Is a Buy

Rocket Lab delivered a blowout Q1, with revenue of $200.3M versus about $190M expected and gross profit of $76.5M versus roughly $73M expected; EPS loss narrowed to ($0.07) from ($0.12) a year ago. Q2 revenue guidance of $225M-$240M also topped the $205M consensus, while backlog reached about $2.2B and new wins included 31 Electron/HASTE missions and 5 Neutron launch agreements. Shares surged 26% on the results, and Stifel raised its price target to $110 from $105 while reiterating Buy.

Analysis

The market is repricing RKLB from “promising launch story” to “credible defense-enabled space infrastructure compounder.” The key second-order effect is that launch is no longer the main valuation driver; the real option value is now the combination of recurring systems revenue, backlog visibility, and defense procurement adjacency, which can support a materially higher multiple if execution stays intact. That said, the stock is starting to trade like a pre-profit platform winner, so the burden shifts from proving demand to proving operating leverage and disciplined capital allocation.

The biggest incremental catalyst is not Neutron itself, but the way Neutron pre-orders and defense demo wins pull forward customer trust and ecosystem lock-in before first flight. If Rocket Lab keeps converting “design-win” activity into funded program work, suppliers and subcontractors may face tighter negotiation power, while smaller launch peers risk being squeezed out of the customer shortlist. RTX and Anduril involvement also broadens the narrative from pure launch to mission assurance and national security infrastructure, which can attract a different investor base and keep the multiple elevated even through lumpy launch cadence.

The risk is that sentiment has likely outrun the fundamental de-risking horizon. Neutron is still a 2026 story, and any technical delay, test anomaly, or cash burn acceleration could trigger a sharp rerating because the equity is now valued on future execution rather than current earnings power. Near term, the stock can continue to squeeze higher on upgrades and backlog commentary, but over the next 6-12 months the main watchpoint is whether gross margin expansion can outpace SG&A and capex growth.

Contrarianly, consensus may be underestimating how much of the “good news” is already forward-filled into the current price after a one-day repricing. The average target sitting below spot implies the next leg higher likely needs either a visible upward revision cycle or a new strategic milestone, not just another solid quarter. In other words, the easy money may be gone, and the better risk/reward may come from buying pullbacks or structuring upside with limited downside rather than chasing strength outright.

Key Decisions for Investors

• Hold/core long RKLB, but add only on 10%-15% post-rally pullbacks over the next 2-6 weeks; the setup remains positive, but chasing after an earnings gap carries poor entry economics.
• Buy RKLB Jan-2027 call spreads to express the Neutron and defense-optionality thesis with defined downside; target a 2:1 or better payoff if management delivers another 2-3 quarters of backlog and margin credibility.
• Pair trade: long RKLB / short a basket of lower-quality small-cap aerospace or launch proxies for 3-6 months; the relative winner should be the name with the strongest backlog conversion and defense relevance, not the one with the loudest narrative.
• If already long, tighten risk: trail stops on 20%-25% of the position and reassess after any Neutron schedule slip or guidance miss, because the stock now trades on execution confidence rather than story appeal.
• Watch for analyst target revisions over the next 1-3 weeks; if consensus moves materially above spot, momentum could extend, but if upgrades stall, expect a digestion phase and rotation out of the trade.